Suppliers

Investigation into Ansun BioPharma dismissed

Inhaled vaccine developer Ansun BioPharma, formerly NexBio, has announced that the US Attorney’s office investigation of misconduct by the company’s former CEO and CFO has been dismissed. As part of that investigation, the US Federal Bureau of Investigation (FBI) raided the California headquarters of NexBio in August 2011.

According to a January 2015 announcement by the US Attorney for the Southern District of California, Ansun agreed to pay $2 million to settle civil and criminal cases against the company.

Current Ansun CEO Ronald Moss said, “We are pleased with the dismissal of the investigation. With new management in place we have made significant progress with our late stage clinical programs for parainfluenza and influenza. We also have developed a pipeline of therapies against other respiratory viruses such as metapneumovirus and eneterovirus68.”

Ansun’s FluDase is a dry powder antiviral for the treatment of influenza, and ParaDase is an inhalation solution delivered by nebulizer for the treatment of parainfluenza.

Read the Ansun BioPharma press release.

published on

July 27, 2015

Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan

September 15-September 18: DDL New Researcher Network Summer Event, London, UK

September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK

October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA

See all upcoming events

Suppliers